A Phase II Study of GC101 in NSCLC
A phase 2 trial of GC101 TIL in non-small-cell lung cancer and small-cell lung cancer, run by Shanghai Juncell Therapeutics, now recruiting.
Overview
A Phase II Study of GC101 in NSCLC is a phase 2 interventional study registered as NCT07560111 by Shanghai Juncell Therapeutics, with 28 participants planned, started 2026-06-01 and due to reach its primary completion in 2027-06-01. Interventions recorded: Autologous Tumor Infiltrating Lymphocytes. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Setting
An Open-Label, Phase II Study to Evaluate the Safety and Efficacy Using Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) in Patients With Non-Small Cell Lung Cancer
Phase
Phase 2
Sponsor
Shanghai Juncell Therapeutics
Registry
Enrolled
28
Similar pages
not linked directly; found by shared links- TrialA Study of GC101 TIL in Advanced Melanoma
Shares Shanghai Juncell Therapeutics, GC101 TIL.
- TargetMEK1/2
Shares GC101 TIL, Non-small-cell lung cancer.